Company Overview and News
MOUNTLAKE TERRACE, Wash. and LACEY, Wash., July 17, 2018 (GLOBE NEWSWIRE) -- FS Bancorp, Inc. ("FS Bancorp ") (NASDAQ:FSBW) and Anchor Bancorp ("Anchor") (NASDAQ:ANCB) announced today the signing of a definitive merger agreement and plan of merger (the “Agreement”) whereby FS Bancorp will acquire Anchor in a stock and cash transaction valued at approximately $77 million. As of March 31, 2018, on a pro forma consolidated basis, the combined company would have approximately $1.
ABCW FSWB SYBJF ANCB WAFD WAFDW FSBW SECB
THE MAIN INDEX eked out last-minute gains on Tuesday after moving within a tight range as investors await the release of corporate earnings results in the coming weeks.
PSKXF BDOUY AYAAY UVRBY SECB BDOUF BDO MWP SYBJF URC PHSXY PSE MWIDE ALI UVRBF AYAAF
THE COUNTRY’S factory production continued to expand by double-digit pace for the fifth straight month in May, though at a slower clip than in the preceding month, the Philippine Statistics Authority (PSA) reported on Thursday.
SYBJF RZLLY RCB SECB
The local stock barometer rallied to the 7,300 level yesterday on the back of some foreign inflows amid expectations that the market may have found the bottom.
BDOUF BDO SMIVY PSKXF SVTMF BDOUY SYBJF PHSXY SM PSE SECB
The local stock barometer yesterday crept higher for the third straight session as domestic investors selectively picked up large-cap stocks dumped by foreign players.
GLO PSKXF GTMEY SYBJF PHSXY PSE GTMEF GLOPP GLOPA SECB
IMPROVEMENT in manufacturing activity eased in June from the preceding month as increases in output and new orders ebbed, according to the latest survey IHS Markit conducted for Nikkei, Inc. that nevertheless showed last month’s “solid” growth pushing the second quarter’s average Purchasing Managers’ Index reading higher than that of January-March.
INFLATION likely clocked in faster in June on the back of rising food and oil prices coupled with a weaker peso, economists said in a BusinessWorld poll, with some noting that another rate hike may still be on the table for the central bank to temper prices.
SYBJF RZLLY RCB SECB
MOUNTLAKE TERRACE, Wash., June 29, 2018 (GLOBE NEWSWIRE) -- FS Bancorp, Inc. (NASDAQ:FSBW), the parent company of 1st Security Bank of Washington, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opened on June 25, as part of the 2018 Russell indexes reconstitution.
FSWB SYBJF FSBW SECB
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET